Quick Takeaways:
- Zoetis launched Portela (relfovetmab) in Canada and the EU, the first long-acting anti-NGF mAb for cats, providing up to 3 months of OA pain relief with one subcutaneous injection. In a pivotal 9-month European study, effectiveness was observed as early as Day 3. Portela was well tolerated in clinical trials.
- Up to 40% of cats may be clinically affected by osteoarthritis, yet only 18% of affected cats are diagnosed with OA pain. Because cats often mask pain and daily oral dosing can be challenging, many remain undertreated. Portela targets NGF at a novel site and is designed for one injection every 3 months.
- Portela expands Zoetis’ feline OA portfolio alongside monthly Solensia (frunevetmab). Zoetis says the longer-acting option may improve treatment convenience and compliance. Subtle signs of feline OA include sleeping more, reduced grooming, and avoiding stairs or high surfaces, highlighting the need for screening and owner education.
Why It Matters?
Zoetis’s Portela launch should expand the feline OA market by turning a hard-to-manage, underdiagnosed condition into a more actionable treatment segment, especially because the therapy offers a three-month injectable option that is easier for owners to keep up with than daily medicines. It also gives Zoetis a stronger premium position alongside Solensia, increasing brand stickiness with vets and pet owners while likely driving more screening, earlier diagnosis, and higher adoption of long-acting pain management in cats.
Source: Businesswire
